查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2134683

兒童流感預防市場－2026年至2032年全球市場預測

Paediatric Influenza Prevention Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，兒童流感預防市場將成長至 22.7 億美元，複合年成長率為 10.14%。

主要市場統計數據
基準年 2025 11.5億美元
預計年份：2026年 12.7億美元
預測年份 2032 22.7億美元
複合年成長率 (%) 10.14%

兒童流感預防：概述

兒童流感預防包括疫苗接種、免疫規劃、衛生措施、監測、在臨床需要時使用抗病毒藥物，以及旨在減少兒童感染和併發症的傳播策略。這一領域受到季節性傳播、各國免疫政策差異、初級保健服務可近性不平等以及保護學校、家庭和高風險族群的需求等因素的影響。有效的預防需要將臨床指南與切實可行的實施體系結合，以確保兒童在流感爆發前和爆發期間都能獲得所需的保護。

預防工作正朝著綜合、公平的實施方向發展。

預防策略正從孤立的疫苗宣傳活動轉向整合兒童醫療保健、學校、藥房、公共衛生機構和社區組織的協調計畫。及時制定季節性指南、明確接種資格標準、提供便利的接種環境，以及為患有慢性疾病或其他風險因素的兒童提供有針對性的支持，正變得越來越重要。數位化提醒、整合註冊系統、社區宣傳以及改進的冷鍊和預約流程，也有助於專案解決錯過接種機會的問題，並提高跨季節接種的連續性。

人工智慧（AI）增強了規劃、監控和個人化回應能力。

人工智慧 (AI) 可以透過識別監測數據中的模式、改善需求預測和預約安排、優先進行推廣活動以及幫助公共衛生團隊解讀兒童臨床和流行病學訊息，從而支持兒童流感預防工作。它還可以幫助客製化提醒和教育內容，以滿足不同家長和社區的需求。然而，負責任地使用人工智慧需要檢驗的數據、隱私保護、透明的決策流程、人工監督以及對偏見的嚴格監控，尤其是在涉及兒童、服務不足人口或不完整健康記錄的情況下。

區域洞察：實施環境影響預防效果

北美地區普遍受惠於完善的免疫基礎設施，但仍面臨季節性疫苗接種率、疫苗取得不均以及醫療服務路徑片段化等挑戰。拉丁美洲的優先事項包括加強常規和季節性疫苗接種的實施、提高冷鏈可靠性以及在都市區、農村和偏遠社區推廣活動。歐洲雖然擁有成熟的監測系統和醫療保健系統，但各國在疫苗接種建議和實施模式方面存在顯著差異。中東地區需要根據不同的醫療保健系統、流動人口和不同的疫苗取得情況制定相應的方案。同時，非洲的優先事項包括疫苗供應可靠性、基層醫療體系、監測以及社區信任。在亞太地區，由於政策和基礎設施狀況各異，制定本地化的疫苗接種計劃、透過學校和社區開展疫苗接種推廣以及確保疫苗公平獲取尤為重要。

群體洞察：政策一致性與存取機制塑造協作行動

儘管東協成員國的醫療衛生系統能力各不相同，但它們都能從協調一致的監控、區域知識交流和靈活的推廣模式中獲益。金磚國家人口規模和疫苗接種環境差異巨大，因此將公平性、國家能力和可互通的監測系統作為關鍵的通用優先事項。歐盟可以利用跨境合作、共用通用技術知識以及在各國靈活的實施結構。七國集團成員國通常擁有強大的研究和交付基礎設施，但必須應對諸如疫苗接種猶豫、獲取途徑不均以及弱勢兒童疫苗接種率差異等挑戰。海灣合作理事會成員國可以利用集中式醫療衛生基礎設施，同時協調為外籍人士和流動人口提供的溝通和服務。北約成員國可以從應對計畫、基本兒童醫療服務的持續性以及針對醫療衛生系統中斷的協調準備工作中獲益。

來自不同國家的見解：每個國家的體係都需要根據其具體需求量身定做的預防策略。

澳洲可以著重關注地域上公平的醫療服務取得以及各州和地區計畫之間的協調。巴西的優先事項包括涵蓋多元化社區、維持初級醫療服務以及縮小區域間醫療服務取得的差距。加拿大必須改善偏遠地區和原住民社區的醫療服務取得，同時兼顧各州和地區的差異。中國可以著重在不同的本地環境中整合廣泛的預防保健、監測以及與看護者的溝通。法國、德國、義大利和西班牙可以繼續加強國家和地區層面的協調，確保季節性和及時性醫療服務的提供，並保護高風險兒童。印度的優先事項包括可擴展的初級醫療服務取得、監測、可負擔的醫療服務以及涵蓋都市區人口的推廣。日本和韓國可以透過及時的季節性規劃和有針對性的看護者合作，進一步加強其強大的醫療衛生系統的能力。墨西哥可以加強在地方和醫療機構中公平的疫苗接種制度。俄羅斯可以專注於疫苗供應的連續性、監測以及確保地域分散的社區都能獲得疫苗。英國可以利用協調一致的指南、在適當的場所開展校內疫苗接種以及為服務不足群體提供有針對性的支持。美國可以繼續努力解決疫苗接種差異、取得障礙、看護者信心以及小兒科、藥房、學校和公共衛生管道之間的協調問題。

領導者指南：預防措施要及時、可衡量、全面。

產業和醫療保健系統領導者應制定季節性準備計劃，整合採購、人員配備、預約安排、公共關係和監測等要素。他們還應透過便捷的疫苗接種點、提醒和加強針通知系統、可互通的記錄以及清晰的臨床規程來減少流程上的摩擦。計畫應根據年齡、健康風險、地點、語言和就醫障礙等因素細分推廣活動，而不是僅依賴籠統的訊息。領導者應制定可衡量的指標，例如接種及時性、錯失機會、建議接種計畫完成率、弱勢群體接種率、不利事件後續處理以及看護者理解程度。人工智慧專案應從嚴格定義的用例、獨立檢驗、健全的管治和定期的公正性審計開始。

調查方法：基於證據的預防系統評估

本執行摘要對兒童流感預防工作進行了結構化評估，涵蓋干預措施、服務管道、政策環境、監測能力、可及性以及技術部署等方面。報告基於既定的公共衛生概念，並結合醫療機構、人口分佈、免疫管治和預防基礎設施等方面的差異，對區域、群體和國家層面進行了定性比較。該分析區分了已觀察到的系統特徵和人工智慧的潛在應用，避免了對商業規模、市場表現或未來結果做出未經證實的斷言。相關解讀應根據國家建議、流行病學情勢和服務實務的變化進行更新。

結論：綜合預防措施能夠保護兒童和社區。

兒童流感預防最有效的前提是疫苗接種和臨床指導能夠得到便利的服務、可靠的監測、值得信賴的溝通以及家庭、學校、醫療機構和公共衛生部門之間的協作。儘管由於地區和國家差異，單一的實施模式並不適用，但通用原則仍然存在：儘早行動、優先關注弱勢兒童、減少實際障礙、衡量公平性以及保持強力的管治。將營運準備與實證創新（包括精心管理的人工智慧）結合的領導力，能夠在確保安全、信任和課責的同時，加強預防措施。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：兒童流感預防市場：依疫苗類型分類

  • 去活化疫苗
    • 分裂的病毒顆粒
    • 次單元
  • 減毒活疫苗
  • 重組疫苗

第8章：兒童流感預防市場：依疫苗技術分類

  • 基於細胞
  • 蛋製品
  • 重組

第9章：兒童流感預防市場：依給藥途徑分類

  • 肌肉內部
  • 鼻內給藥

第10章：兒童流感預防市場：依年齡層別分類

  • 2至8歲
  • 6個月至23個月大
  • 9-17歲

第11章：兒童流感預防市場：依劑型分類

  • 多管瓶小瓶
    • 10劑裝管瓶
    • 5劑裝管瓶
  • 單劑量注射器

第12章：兒童流感預防市場：依分銷管道分類

  • 私部門
    • 醫院藥房
    • 零售藥房
  • 公部門

第13章：兒童流感預防市場：依最終用戶分類

  • 診所
    • 基層醫療診所
    • 專科診所
  • 醫院

第14章：兒童流感預防市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第15章：兒童流感預防市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：兒童流感預防市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • Abbott Laboratories
  • Altimmune, Inc.
  • AstraZeneca plc
  • Bharat Biotech International Ltd.
  • BioCryst Pharmaceuticals, Inc.
  • China National Pharmaceutical Group Co., Ltd.
  • CSL Limited
  • Daiichi Sankyo Company, Limited
  • FluGen, Inc.
  • GlaxoSmithKline plc
  • Hualan Biological Engineering Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novavax, Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Seqirus
  • Serum Institute of India Pvt. Ltd.
  • Sinovac Biotech Ltd.
  • SK Bioscience Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Vaxart, Inc.
  • Viatris Inc.

第19章 主要專家

Product Code: MRR-F774F6337039

The Paediatric Influenza Prevention Market is projected to grow by USD 2.27 billion at a CAGR of 10.14% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.15 billion
Estimated Year [2026] USD 1.27 billion
Forecast Year [2032] USD 2.27 billion
CAGR (%) 10.14%

Paediatric Influenza Prevention: Executive Overview

Paediatric influenza prevention encompasses vaccination, immunisation delivery, hygiene measures, surveillance, antiviral use when clinically indicated, and communication strategies designed to reduce infection and complications among children. The field is shaped by seasonal transmission, differences in national immunisation policy, unequal access to primary care, and the need to protect schools, households, and vulnerable contacts. Effective prevention combines clinical guidance with practical delivery systems that reach children reliably before and during influenza seasons.

Prevention Is Shifting Toward Integrated, Equitable Delivery

The prevention landscape is moving from isolated vaccination campaigns toward coordinated programmes linking paediatric care, schools, pharmacies, public-health agencies, and community organisations. Greater emphasis is being placed on timely seasonal planning, clear eligibility guidance, convenient administration settings, and targeted outreach to children with chronic conditions or other risk factors. Digital reminders, registry integration, community education, and stronger cold-chain and appointment workflows are also helping programmes address missed opportunities and improve continuity across seasons.

Artificial Intelligence Strengthens Planning, Surveillance, and Personalisation

Artificial intelligence can support paediatric influenza prevention by identifying patterns in surveillance data, improving demand and appointment planning, prioritising outreach, and assisting public-health teams in interpreting large volumes of clinical and epidemiological information. It may also help tailor reminders and educational content to different caregivers and communities. However, responsible use requires validated data, privacy safeguards, transparent decision processes, human oversight, and careful monitoring for bias-particularly where children, underserved populations, or incomplete health records are involved.

Regional Insights: Delivery Context Determines Prevention Outcomes

North America generally benefits from established immunisation infrastructure but continues to face challenges involving seasonal uptake, access disparities, and fragmented care pathways. Latin America's priorities include strengthening routine and seasonal delivery, cold-chain reliability, and outreach across urban, rural, and remote communities. Europe combines mature surveillance and health systems with substantial variation in national recommendations and delivery models. The Middle East requires approaches suited to diverse health systems, mobile populations, and differing access conditions, while Africa's priorities include supply reliability, primary-care capacity, surveillance, and community trust. Asia-Pacific presents a wide range of policy and infrastructure settings, making locally adapted schedules, school and community delivery, and equitable access especially important.

Group Insights: Policy Alignment and Access Shape Collective Action

ASEAN members face varied health-system capacity and benefit from coordinated surveillance, regional knowledge exchange, and adaptable outreach models. BRICS countries span highly diverse population sizes and delivery environments, making equity, domestic capacity, and interoperable surveillance important shared priorities. The European Union can leverage cross-border coordination, common technical learning, and national implementation flexibility. G7 members typically have strong research and delivery infrastructure but must address hesitancy, access gaps, and differences in coverage among vulnerable children. GCC countries can build on concentrated healthcare infrastructure while tailoring communication and services for expatriate and mobile populations. NATO members may benefit from resilience planning, continuity of essential paediatric services, and coordinated preparedness for health-system disruption.

Country Insights: National Systems Require Tailored Prevention Strategies

Australia can emphasise geographically equitable access and coordination across state and territory programmes. Brazil's priorities include reaching diverse communities, sustaining primary-care delivery, and addressing regional access differences. Canada must account for provincial and territorial variation while improving consistent access for remote and Indigenous communities. China can focus on broad preventive-care integration, surveillance, and caregiver communication across diverse local settings. France, Germany, Italy, and Spain can continue refining national and regional coordination, timely seasonal delivery, and protection of children with elevated clinical risk. India's priorities include scalable primary-care access, surveillance, affordability, and outreach across urban and rural populations. Japan and South Korea can build on strong health-system capabilities through timely seasonal planning and targeted caregiver engagement. Mexico can strengthen equitable delivery across regions and healthcare settings. Russia can focus on continuity of supply, surveillance, and access across geographically dispersed communities. The United Kingdom can use coordinated guidance, school-linked delivery where appropriate, and targeted support for underserved groups. The United States can continue addressing coverage variation, access barriers, caregiver confidence, and integration among paediatric, pharmacy, school, and public-health channels.

Actions for Leaders: Make Prevention Timely, Measurable, and Inclusive

Industry and health-system leaders should establish seasonal readiness plans that connect procurement, workforce capacity, appointment availability, communications, and surveillance. They should reduce friction through convenient delivery sites, reminder and recall systems, interoperable records, and clear clinical protocols. Programmes should segment outreach according to age, medical risk, geography, language, and access barriers rather than relying on broad messaging alone. Leaders should define measurable indicators such as timeliness, missed-opportunity rates, completion of recommended schedules, access by underserved group, adverse-event follow-up, and caregiver understanding. AI initiatives should begin with narrowly defined use cases, independent validation, strong governance, and routine equity audits.

Research Methodology: Evidence-Led Assessment of Prevention Systems

This executive summary uses a structured assessment of paediatric influenza prevention across interventions, delivery channels, policy environments, surveillance capabilities, access conditions, and technology adoption. Regional, group, and country comparisons are presented qualitatively, based on established public-health concepts and documented differences in healthcare organisation, population distribution, immunisation governance, and prevention infrastructure. The analysis separates observed system characteristics from potential applications of artificial intelligence and avoids unsupported claims about commercial scale, market performance, or future outcomes. Interpretation should be updated as national recommendations, epidemiological conditions, and delivery practices change.

Conclusion: Integrated Prevention Protects Children and Communities

Paediatric influenza prevention is most effective when vaccination and clinical guidance are supported by accessible services, dependable surveillance, trusted communication, and coordinated action across families, schools, providers, and public-health authorities. Regional and national differences make a single delivery model unsuitable, but common principles remain: act early, prioritise vulnerable children, reduce practical barriers, measure equity, and maintain strong governance. Leaders that combine operational readiness with evidence-based innovation-including carefully governed artificial intelligence-can strengthen prevention while preserving safety, trust, and accountability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Paediatric Influenza Prevention Market, by Vaccine Type

  • 7.1. Introduction
  • 7.2. Inactivated Vaccine
    • 7.2.1. Split Virion
    • 7.2.2. Subunit
  • 7.3. Live Attenuated Vaccine
  • 7.4. Recombinant Vaccine

8. Paediatric Influenza Prevention Market, by Vaccine Technology

  • 8.1. Introduction
  • 8.2. Cell-Based
  • 8.3. Egg-Based
  • 8.4. Recombinant

9. Paediatric Influenza Prevention Market, by Route Of Administration

  • 9.1. Introduction
  • 9.2. Intramuscular
  • 9.3. Intranasal

10. Paediatric Influenza Prevention Market, by Age Group

  • 10.1. Introduction
  • 10.2. 2 To 8 Years
  • 10.3. 6 To 23 Months
  • 10.4. 9 To 17 Years

11. Paediatric Influenza Prevention Market, by Dosing Format

  • 11.1. Introduction
  • 11.2. Multi Dose Vial
    • 11.2.1. 10 Dose Vial
    • 11.2.2. 5 Dose Vial
  • 11.3. Single Dose Syringe

12. Paediatric Influenza Prevention Market, by Distribution Channel

  • 12.1. Introduction
  • 12.2. Private Sector
    • 12.2.1. Hospital Pharmacies
    • 12.2.2. Retail Pharmacies
  • 12.3. Public Sector

13. Paediatric Influenza Prevention Market, by End User

  • 13.1. Introduction
  • 13.2. Clinics
    • 13.2.1. Primary Care Clinics
    • 13.2.2. Specialty Clinics
  • 13.3. Hospitals

14. Paediatric Influenza Prevention Market, by Region

  • 14.1. Introduction
  • 14.2. Asia-Pacific
  • 14.3. North America
  • 14.4. Latin America
  • 14.5. Europe
  • 14.6. Middle East
  • 14.7. Africa

15. Paediatric Influenza Prevention Market, by Group

  • 15.1. Introduction
  • 15.2. ASEAN
  • 15.3. GCC
  • 15.4. European Union
  • 15.5. BRICS
  • 15.6. G7
  • 15.7. NATO

16. Paediatric Influenza Prevention Market, by Country

  • 16.1. Introduction
  • 16.2. United States
  • 16.3. Canada
  • 16.4. Mexico
  • 16.5. Brazil
  • 16.6. United Kingdom
  • 16.7. Germany
  • 16.8. France
  • 16.9. Russia
  • 16.10. Italy
  • 16.11. Spain
  • 16.12. China
  • 16.13. India
  • 16.14. Japan
  • 16.15. Australia
  • 16.16. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2025
  • 17.2. Market Concentration Analysis, 2025
    • 17.2.1. Concentration Ratio (CR)
    • 17.2.2. Herfindahl Hirschman Index (HHI)
  • 17.3. Recent Developments & Impact Analysis, 2025
  • 17.4. Product Portfolio Analysis, 2025
  • 17.5. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. Abbott Laboratories
  • 18.2. Altimmune, Inc.
  • 18.3. AstraZeneca plc
  • 18.4. Bharat Biotech International Ltd.
  • 18.5. BioCryst Pharmaceuticals, Inc.
  • 18.6. China National Pharmaceutical Group Co., Ltd.
  • 18.7. CSL Limited
  • 18.8. Daiichi Sankyo Company, Limited
  • 18.9. FluGen, Inc.
  • 18.10. GlaxoSmithKline plc
  • 18.11. Hualan Biological Engineering Inc.
  • 18.12. Johnson & Johnson
  • 18.13. Merck & Co., Inc.
  • 18.14. Mitsubishi Tanabe Pharma Corporation
  • 18.15. Novavax, Inc.
  • 18.16. Pfizer Inc.
  • 18.17. Sanofi S.A.
  • 18.18. Seqirus
  • 18.19. Serum Institute of India Pvt. Ltd.
  • 18.20. Sinovac Biotech Ltd.
  • 18.21. SK Bioscience Co., Ltd.
  • 18.22. Takeda Pharmaceutical Company Limited
  • 18.23. Teva Pharmaceutical Industries Ltd.
  • 18.24. Vaxart, Inc.
  • 18.25. Viatris Inc.

19. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Paediatric Influenza Prevention Market, Years Considered for the Study
  • FIGURE 2. Global Paediatric Influenza Prevention Market, Research Design
  • FIGURE 3. Global Paediatric Influenza Prevention Market, Research Framework
  • FIGURE 4. Global Paediatric Influenza Prevention Market, Data Triangulation
  • FIGURE 5. Global Paediatric Influenza Prevention Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Paediatric Influenza Prevention Market Size, by Vaccine Type, 2025 vs 2032 (%)
  • FIGURE 7. Global Paediatric Influenza Prevention Market Size, by Vaccine Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Paediatric Influenza Prevention Market Size, by Vaccine Technology, 2025 vs 2032 (%)
  • FIGURE 9. Global Paediatric Influenza Prevention Market Size, by Vaccine Technology, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Paediatric Influenza Prevention Market Size, by Route Of Administration, 2025 vs 2032 (%)
  • FIGURE 11. Global Paediatric Influenza Prevention Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Paediatric Influenza Prevention Market Size, by Age Group, 2025 vs 2032 (%)
  • FIGURE 13. Global Paediatric Influenza Prevention Market Size, by Age Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Paediatric Influenza Prevention Market Size, by Dosing Format, 2025 vs 2032 (%)
  • FIGURE 15. Global Paediatric Influenza Prevention Market Size, by Dosing Format, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Paediatric Influenza Prevention Market Size, by Distribution Channel, 2025 vs 2032 (%)
  • FIGURE 17. Global Paediatric Influenza Prevention Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global Paediatric Influenza Prevention Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 19. Global Paediatric Influenza Prevention Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 20. Global Paediatric Influenza Prevention Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 21. Global Paediatric Influenza Prevention Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 22. Global Paediatric Influenza Prevention Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 23. Global Paediatric Influenza Prevention Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 24. Global Paediatric Influenza Prevention Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 25. Global Paediatric Influenza Prevention Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Paediatric Influenza Prevention Market Segmentation & Coverage
  • TABLE 2. Global Paediatric Influenza Prevention Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Paediatric Influenza Prevention Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 4. Global Inactivated Vaccine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Inactivated Vaccine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Inactivated Vaccine Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Split Virion Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Split Virion Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Split Virion Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Subunit Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Subunit Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Subunit Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Live Attenuated Vaccine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global Live Attenuated Vaccine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global Live Attenuated Vaccine Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global Recombinant Vaccine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 17. Global Recombinant Vaccine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 18. Global Recombinant Vaccine Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 19. Global Paediatric Influenza Prevention Market Size, by Vaccine Technology, 2017-2032 (USD Million)
  • TABLE 20. Global Cell-Based Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 21. Global Cell-Based Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 22. Global Cell-Based Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 23. Global Egg-Based Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 24. Global Egg-Based Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 25. Global Egg-Based Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 26. Global Recombinant Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 27. Global Recombinant Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 28. Global Recombinant Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 29. Global Paediatric Influenza Prevention Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 30. Global Intramuscular Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 31. Global Intramuscular Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 32. Global Intramuscular Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 33. Global Intranasal Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 34. Global Intranasal Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 35. Global Intranasal Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 36. Global Paediatric Influenza Prevention Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 37. Global 2 To 8 Years Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 38. Global 2 To 8 Years Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 39. Global 2 To 8 Years Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 40. Global 6 To 23 Months Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 41. Global 6 To 23 Months Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 42. Global 6 To 23 Months Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 43. Global 9 To 17 Years Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 44. Global 9 To 17 Years Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 45. Global 9 To 17 Years Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 46. Global Paediatric Influenza Prevention Market Size, by Dosing Format, 2017-2032 (USD Million)
  • TABLE 47. Global Multi Dose Vial Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 48. Global Multi Dose Vial Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 49. Global Multi Dose Vial Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 50. Global 10 Dose Vial Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 51. Global 10 Dose Vial Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 52. Global 10 Dose Vial Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 53. Global 5 Dose Vial Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 54. Global 5 Dose Vial Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 55. Global 5 Dose Vial Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 56. Global Single Dose Syringe Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 57. Global Single Dose Syringe Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 58. Global Single Dose Syringe Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 59. Global Paediatric Influenza Prevention Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 60. Global Private Sector Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 61. Global Private Sector Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 62. Global Private Sector Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 63. Global Hospital Pharmacies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 64. Global Hospital Pharmacies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 65. Global Hospital Pharmacies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 66. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 67. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 68. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 69. Global Public Sector Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 70. Global Public Sector Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 71. Global Public Sector Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 72. Global Paediatric Influenza Prevention Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 73. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 74. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 75. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 76. Global Primary Care Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 77. Global Primary Care Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 78. Global Primary Care Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 79. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 80. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 81. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 82. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 83. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 84. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 85. Global Paediatric Influenza Prevention Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 86. Asia-Pacific Paediatric Influenza Prevention Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 87. Asia-Pacific Paediatric Influenza Prevention Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 88. Asia-Pacific Paediatric Influenza Prevention Market Size, by Inactivated Vaccine, 2017-2032 (USD Million)
  • TABLE 89. Asia-Pacific Paediatric Influenza Prevention Market Size, by Vaccine Technology, 2017-2032 (USD Million)
  • TABLE 90. Asia-Pacific Paediatric Influenza Prevention Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 91. Asia-Pacific Paediatric Influenza Prevention Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 92. Asia-Pacific Paediatric Influenza Prevention Market Size, by Dosing Format, 2017-2032 (USD Million)
  • TABLE 93. Asia-Pacific Paediatric Influenza Prevention Market Size, by Multi Dose Vial, 2017-2032 (USD Million)
  • TABLE 94. Asia-Pacific Paediatric Influenza Prevention Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 95. Asia-Pacific Paediatric Influenza Prevention Market Size, by Private Sector, 2017-2032 (USD Million)
  • TABLE 96. Asia-Pacific Paediatric Influenza Prevention Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 97. Asia-Pacific Paediatric Influenza Prevention Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 98. North America Paediatric Influenza Prevention Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 99. North America Paediatric Influenza Prevention Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 100. North America Paediatric Influenza Prevention Market Size, by Inactivated Vaccine, 2017-2032 (USD Million)
  • TABLE 101. North America Paediatric Influenza Prevention Market Size, by Vaccine Technology, 2017-2032 (USD Million)
  • TABLE 102. North America Paediatric Influenza Prevention Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 103. North America Paediatric Influenza Prevention Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 104. North America Paediatric Influenza Prevention Market Size, by Dosing Format, 2017-2032 (USD Million)
  • TABLE 105. North America Paediatric Influenza Prevention Market Size, by Multi Dose Vial, 2017-2032 (USD Million)
  • TABLE 106. North America Paediatric Influenza Prevention Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 107. North America Paediatric Influenza Prevention Market Size, by Private Sector, 2017-2032 (USD Million)
  • TABLE 108. North America Paediatric Influenza Prevention Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 109. North America Paediatric Influenza Prevention Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 110. Latin America Paediatric Influenza Prevention Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 111. Latin America Paediatric Influenza Prevention Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 112. Latin America Paediatric Influenza Prevention Market Size, by Inactivated Vaccine, 2017-2032 (USD Million)
  • TABLE 113. Latin America Paediatric Influenza Prevention Market Size, by Vaccine Technology, 2017-2032 (USD Million)
  • TABLE 114. Latin America Paediatric Influenza Prevention Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 115. Latin America Paediatric Influenza Prevention Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 116. Latin America Paediatric Influenza Prevention Market Size, by Dosing Format, 2017-2032 (USD Million)
  • TABLE 117. Latin America Paediatric Influenza Prevention Market Size, by Multi Dose Vial, 2017-2032 (USD Million)
  • TABLE 118. Latin America Paediatric Influenza Prevention Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 119. Latin America Paediatric Influenza Prevention Market Size, by Private Sector, 2017-2032 (USD Million)
  • TABLE 120. Latin America Paediatric Influenza Prevention Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 121. Latin America Paediatric Influenza Prevention Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 122. Europe Paediatric Influenza Prevention Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 123. Europe Paediatric Influenza Prevention Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 124. Europe Paediatric Influenza Prevention Market Size, by Inactivated Vaccine, 2017-2032 (USD Million)
  • TABLE 125. Europe Paediatric Influenza Prevention Market Size, by Vaccine Technology, 2017-2032 (USD Million)
  • TABLE 126. Europe Paediatric Influenza Prevention Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 127. Europe Paediatric Influenza Prevention Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 128. Europe Paediatric Influenza Prevention Market Size, by Dosing Format, 2017-2032 (USD Million)
  • TABLE 129. Europe Paediatric Influenza Prevention Market Size, by Multi Dose Vial, 2017-2032 (USD Million)
  • TABLE 130. Europe Paediatric Influenza Prevention Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 131. Europe Paediatric Influenza Prevention Market Size, by Private Sector, 2017-2032 (USD Million)
  • TABLE 132. Europe Paediatric Influenza Prevention Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 133. Europe Paediatric Influenza Prevention Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 134. Middle East Paediatric Influenza Prevention Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 135. Middle East Paediatric Influenza Prevention Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 136. Middle East Paediatric Influenza Prevention Market Size, by Inactivated Vaccine, 2017-2032 (USD Million)
  • TABLE 137. Middle East Paediatric Influenza Prevention Market Size, by Vaccine Technology, 2017-2032 (USD Million)
  • TABLE 138. Middle East Paediatric Influenza Prevention Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 139. Middle East Paediatric Influenza Prevention Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 140. Middle East Paediatric Influenza Prevention Market Size, by Dosing Format, 2017-2032 (USD Million)
  • TABLE 141. Middle East Paediatric Influenza Prevention Market Size, by Multi Dose Vial, 2017-2032 (USD Million)
  • TABLE 142. Middle East Paediatric Influenza Prevention Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 143. Middle East Paediatric Influenza Prevention Market Size, by Private Sector, 2017-2032 (USD Million)
  • TABLE 144. Middle East Paediatric Influenza Prevention Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 145. Middle East Paediatric Influenza Prevention Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 146. Africa Paediatric Influenza Prevention Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 147. Africa Paediatric Influenza Prevention Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 148. Africa Paediatric Influenza Prevention Market Size, by Inactivated Vaccine, 2017-2032 (USD Million)
  • TABLE 149. Africa Paediatric Influenza Prevention Market Size, by Vaccine Technology, 2017-2032 (USD Million)
  • TABLE 150. Africa Paediatric Influenza Prevention Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 151. Africa Paediatric Influenza Prevention Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 152. Africa Paediatric Influenza Prevention Market Size, by Dosing Format, 2017-2032 (USD Million)
  • TABLE 153. Africa Paediatric Influenza Prevention Market Size, by Multi Dose Vial, 2017-2032 (USD Million)
  • TABLE 154. Africa Paediatric Influenza Prevention Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 155. Africa Paediatric Influenza Prevention Market Size, by Private Sector, 2017-2032 (USD Million)
  • TABLE 156. Africa Paediatric Influenza Prevention Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 157. Africa Paediatric Influenza Prevention Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 158. Global Paediatric Influenza Prevention Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 159. ASEAN Paediatric Influenza Prevention Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 160. ASEAN Paediatric Influenza Prevention Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 161. ASEAN Paediatric Influenza Prevention Market Size, by Inactivated Vaccine, 2017-2032 (USD Million)
  • TABLE 162. ASEAN Paediatric Influenza Prevention Market Size, by Vaccine Technology, 2017-2032 (USD Million)
  • TABLE 163. ASEAN Paediatric Influenza Prevention Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 164. ASEAN Paediatric Influenza Prevention Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 165. ASEAN Paediatric Influenza Prevention Market Size, by Dosing Format, 2017-2032 (USD Million)
  • TABLE 166. ASEAN Paediatric Influenza Prevention Market Size, by Multi Dose Vial, 2017-2032 (USD Million)
  • TABLE 167. ASEAN Paediatric Influenza Prevention Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 168. ASEAN Paediatric Influenza Prevention Market Size, by Private Sector, 2017-2032 (USD Million)
  • TABLE 169. ASEAN Paediatric Influenza Prevention Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 170. ASEAN Paediatric Influenza Prevention Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 171. GCC Paediatric Influenza Prevention Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 172. GCC Paediatric Influenza Prevention Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 173. GCC Paediatric Influenza Prevention Market Size, by Inactivated Vaccine, 2017-2032 (USD Million)
  • TABLE 174. GCC Paediatric Influenza Prevention Market Size, by Vaccine Technology, 2017-2032 (USD Million)
  • TABLE 175. GCC Paediatric Influenza Prevention Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 176. GCC Paediatric Influenza Prevention Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 177. GCC Paediatric Influenza Prevention Market Size, by Dosing Format, 2017-2032 (USD Million)
  • TABLE 178. GCC Paediatric Influenza Prevention Market Size, by Multi Dose Vial, 2017-2032 (USD Million)
  • TABLE 179. GCC Paediatric Influenza Prevention Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 180. GCC Paediatric Influenza Prevention Market Size, by Private Sector, 2017-2032 (USD Million)
  • TABLE 181. GCC Paediatric Influenza Prevention Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 182. GCC Paediatric Influenza Prevention Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 183. European Union Paediatric Influenza Prevention Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 184. European Union Paediatric Influenza Prevention Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 185. European Union Paediatric Influenza Prevention Market Size, by Inactivated Vaccine, 2017-2032 (USD Million)
  • TABLE 186. European Union Paediatric Influenza Prevention Market Size, by Vaccine Technology, 2017-2032 (USD Million)
  • TABLE 187. European Union Paediatric Influenza Prevention Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 188. European Union Paediatric Influenza Prevention Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 189. European Union Paediatric Influenza Prevention Market Size, by Dosing Format, 2017-2032 (USD Million)
  • TABLE 190. European Union Paediatric Influenza Prevention Market Size, by Multi Dose Vial, 2017-2032 (USD Million)
  • TABLE 191. European Union Paediatric Influenza Prevention Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 192. European Union Paediatric Influenza Prevention Market Size, by Private Sector, 2017-2032 (USD Million)
  • TABLE 193. European Union Paediatric Influenza Prevention Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 194. European Union Paediatric Influenza Prevention Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 195. BRICS Paediatric Influenza Prevention Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 196. BRICS Paediatric Influenza Prevention Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 197. BRICS Paediatric Influenza Prevention Market Size, by Inactivated Vaccine, 2017-2032 (USD Million)
  • TABLE 198. BRICS Paediatric Influenza Prevention Market Size, by Vaccine Technology, 2017-2032 (USD Million)
  • TABLE 199. BRICS Paediatric Influenza Prevention Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 200. BRICS Paediatric Influenza Prevention Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 201. BRICS Paediatric Influenza Prevention Market Size, by Dosing Format, 2017-2032 (USD Million)
  • TABLE 202. BRICS Paediatric Influenza Prevention Market Size, by Multi Dose Vial, 2017-2032 (USD Million)
  • TABLE 203. BRICS Paediatric Influenza Prevention Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 204. BRICS Paediatric Influenza Prevention Market Size, by Private Sector, 2017-2032 (USD Million)
  • TABLE 205. BRICS Paediatric Influenza Prevention Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 206. BRICS Paediatric Influenza Prevention Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 207. G7 Paediatric Influenza Prevention Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 208. G7 Paediatric Influenza Prevention Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 209. G7 Paediatric Influenza Prevention Market Size, by Inactivated Vaccine, 2017-2032 (USD Million)
  • TABLE 210. G7 Paediatric Influenza Prevention Market Size, by Vaccine Technology, 2017-2032 (USD Million)
  • TABLE 211. G7 Paediatric Influenza Prevention Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 212. G7 Paediatric Influenza Prevention Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 213. G7 Paediatric Influenza Prevention Market Size, by Dosing Format, 2017-2032 (USD Million)
  • TABLE 214. G7 Paediatric Influenza Prevention Market Size, by Multi Dose Vial, 2017-2032 (USD Million)
  • TABLE 215. G7 Paediatric Influenza Prevention Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 216. G7 Paediatric Influenza Prevention Market Size, by Private Sector, 2017-2032 (USD Million)
  • TABLE 217. G7 Paediatric Influenza Prevention Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 218. G7 Paediatric Influenza Prevention Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 219. NATO Paediatric Influenza Prevention Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 220. NATO Paediatric Influenza Prevention Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 221. NATO Paediatric Influenza Prevention Market Size, by Inactivated Vaccine, 2017-2032 (USD Million)
  • TABLE 222. NATO Paediatric Influenza Prevention Market Size, by Vaccine Technology, 2017-2032 (USD Million)
  • TABLE 223. NATO Paediatric Influenza Prevention Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 224. NATO Paediatric Influenza Prevention Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 225. NATO Paediatric Influenza Prevention Market Size, by Dosing Format, 2017-2032 (USD Million)
  • TABLE 226. NATO Paediatric Influenza Prevention Market Size, by Multi Dose Vial, 2017-2032 (USD Million)
  • TABLE 227. NATO Paediatric Influenza Prevention Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 228. NATO Paediatric Influenza Prevention Market Size, by Private Sector, 2017-2032 (USD Million)
  • TABLE 229. NATO Paediatric Influenza Prevention Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 230. NATO Paediatric Influenza Prevention Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 231. Global Paediatric Influenza Prevention Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 232. United States Paediatric Influenza Prevention Market Size, 2017-2032 (USD Million)
  • TABLE 233. United States Paediatric Influenza Prevention Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 234. United States Paediatric Influenza Prevention Market Size, by Inactivated Vaccine, 2017-2032 (USD Million)
  • TABLE 235. United States Paediatric Influenza Prevention Market Size, by Vaccine Technology, 2017-2032 (USD Million)
  • TABLE 236. United States Paediatric Influenza Prevention Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 237. United States Paediatric Influenza Prevention Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 238. United States Paediatric Influenza Prevention Market Size, by Dosing Format, 2017-2032 (USD Million)
  • TABLE 239. United States Paediatric Influenza Prevention Market Size, by Multi Dose Vial, 2017-2032 (USD Million)
  • TABLE 240. United States Paediatric Influenza Prevention Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 241. United States Paediatric Influenza Prevention Market Size, by Private Sector, 2017-2032 (USD Million)
  • TABLE 242. United States Paediatric Influenza Prevention Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 243. United States Paediatric Influenza Prevention Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 244. Canada Paediatric Influenza Prevention Market Size, 2017-2032 (USD Million)
  • TABLE 245. Canada Paediatric Influenza Prevention Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 246. Canada Paediatric Influenza Prevention Market Size, by Inactivated Vaccine, 2017-2032 (USD Million)
  • TABLE 247. Canada Paediatric Influenza Prevention Market Size, by Vaccine Technology, 2017-2032 (USD Million)
  • TABLE 248. Canada Paediatric Influenza Prevention Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 249. Canada Paediatric Influenza Prevention Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 250. Canada Paediatric Influenza Prevention Market Size, by Dosing Format, 2017-2032 (USD Million)
  • TABLE 251. Canada Paediatric Influenza Prevention Market Size, by Multi Dose Vial, 2017-2032 (USD Million)
  • TABLE 252. Canada Paediatric Influenza Prevention Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 253. Canada Paediatric Influenza Prevention Market Size, by Private Sector, 2017-2032 (USD Million)
  • TABLE 254. Canada Paediatric Influenza Prevention Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 255. Canada Paediatric Influenza Prevention Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 256. Mexico Paediatric Influenza Prevention Market Size, 2017-2032 (USD Million)
  • TABLE 257. Mexico Paediatric Influenza Prevention Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 258. Mexico Paediatric Influenza Prevention Market Size, by Inactivated Vaccine, 2017-2032 (USD Million)
  • TABLE 259. Mexico Paediatric Influenza Prevention Market Size, by Vaccine Technology, 2017-2032 (USD Million)
  • TABLE 260. Mexico Paediatric Influenza Prevention Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 261. Mexico Paediatric Influenza Prevention Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 262. Mexico Paediatric Influenza Prevention Market Size, by Dosing Format, 2017-2032 (USD Million)
  • TABLE 263. Mexico Paediatric Influenza Prevention Market Size, by Multi Dose Vial, 2017-2032 (USD Million)
  • TABLE 264. Mexico Paediatric Influenza Prevention Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 265. Mexico Paediatric Influenza Prevention Market Size, by Private Sector, 2017-2032 (USD Million)
  • TABLE 266. Mexico Paediatric Influenza Prevention Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 267. Mexico Paediatric Influenza Prevention Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 268. Brazil Paediatric Influenza Prevention Market Size, 2017-2032 (USD Million)
  • TABLE 269. Brazil Paediatric Influenza Prevention Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 270. Brazil Paediatric Influenza Prevention Market Size, by Inactivated Vaccine, 2017-2032 (USD Million)
  • TABLE 271. Brazil Paediatric Influenza Prevention Market Size, by Vaccine Technology, 2017-2032 (USD Million)
  • TABLE 272. Brazil Paediatric Influenza Prevention Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 273. Brazil Paediatric Influenza Prevention Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 274. Brazil Paediatric Influenza Prevention Market Size, by Dosing Format, 2017-2032 (USD Million)
  • TABLE 275. Brazil Paediatric Influenza Prevention Market Size, by Multi Dose Vial, 2017-2032 (USD Million)
  • TABLE 276. Brazil Paediatric Influenza Prevention Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 277. Brazil Paediatric Influenza Prevention Market Size, by Private Sector, 2017-2032 (USD Million)
  • TABLE 278. Brazil Paediatric Influenza Prevention Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 279. Brazil Paediatric Influenza Prevention Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 280. United Kingdom Paediatric Influenza Prevention Market Size, 2017-2032 (USD Million)
  • TABLE 281. United Kingdom Paediatric Influenza Prevention Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 282. United Kingdom Paediatric Influenza Prevention Market Size, by Inactivated Vaccine, 2017-2032 (USD Million)
  • TABLE 283. United Kingdom Paediatric Influenza Prevention Market Size, by Vaccine Technology, 2017-2032 (USD Million)
  • TABLE 284. United Kingdom Paediatric Influenza Prevention Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 285. United Kingdom Paediatric Influenza Prevention Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 286. United Kingdom Paediatric Influenza Prevention Market Size, by Dosing Format, 2017-2032 (USD Million)
  • TABLE 287. United Kingdom Paediatric Influenza Prevention Market Size, by Multi Dose Vial, 2017-2032 (USD Million)
  • TABLE 288. United Kingdom Paediatric Influenza Prevention Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 289. United Kingdom Paediatric Influenza Prevention Market Size, by Private Sector, 2017-2032 (USD Million)
  • TABLE 290. United Kingdom Paediatric Influenza Prevention Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 291. United Kingdom Paediatric Influenza Prevention Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 292. Germany Paediatric Influenza Prevention Market Size, 2017-2032 (USD Million)
  • TABLE 293. Germany Paediatric Influenza Prevention Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 294. Germany Paediatric Influenza Prevention Market Size, by Inactivated Vaccine, 2017-2032 (USD Million)
  • TABLE 295. Germany Paediatric Influenza Prevention Market Size, by Vaccine Technology, 2017-2032 (USD Million)
  • TABLE 296. Germany Paediatric Influenza Prevention Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 297. Germany Paediatric Influenza Prevention Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 298. Germany Paediatric Influenza Prevention Market Size, by Dosing Format, 2017-2032 (USD Million)
  • TABLE 299. Germany Paediatric Influenza Prevention Market Size, by Multi Dose Vial, 2017-2032 (USD Million)
  • TABLE 300. Germany Paediatric Influenza Prevention Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 301. Germany Paediatric Influenza Prevention Market Size, by Private Sector, 2017-2032 (USD Million)
  • TABLE 302. Germany Paediatric Influenza Prevention Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 303. Germany Paediatric Influenza Prevention Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 304. France Paediatric Influenza Prevention Market Size, 2017-2032 (USD Million)
  • TABLE 305. France Paediatric Influenza Prevention Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 306. France Paediatric Influenza Prevention Market Size, by Inactivated Vaccine, 2017-2032 (USD Million)
  • TABLE 307. France Paediatric Influenza Prevention Market Size, by Vaccine Technology, 2017-2032 (USD Million)
  • TABLE 308. France Paediatric Influenza Prevention Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 309. France Paediatric Influenza Prevention Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 310. France Paediatric Influenza Prevention Market Size, by Dosing Format, 2017-2032 (USD Million)
  • TABLE 311. France Paediatric Influenza Prevention Market Size, by Multi Dose Vial, 2017-2032 (USD Million)
  • TABLE 312. France Paediatric Influenza Prevention Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 313. France Paediatric Influenza Prevention Market Size, by Private Sector, 2017-2032 (USD Million)
  • TABLE 314. France Paediatric Influenza Prevention Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 315. France Paediatric Influenza Prevention Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 316. Russia Paediatric Influenza Prevention Market Size, 2017-2032 (USD Million)
  • TABLE 317. Russia Paediatric Influenza Prevention Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 318. Russia Paediatric Influenza Prevention Market Size, by Inactivated Vaccine, 2017-2032 (USD Million)
  • TABLE 319. Russia Paediatric Influenza Prevention Market Size, by Vaccine Technology, 2017-2032 (USD Million)
  • TABLE 320. Russia Paediatric Influenza Prevention Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 321. Russia Paediatric Influenza Prevention Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 322. Russia Paediatric Influenza Prevention Market Size, by Dosing Format, 2017-2032 (USD Million)
  • TABLE 323. Russia Paediatric Influenza Prevention Market Size, by Multi Dose Vial, 2017-2032 (USD Million)
  • TABLE 324. Russia Paediatric Influenza Prevention Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 325. Russia Paediatric Influenza Prevention Market Size, by Private Sector, 2017-2032 (USD Million)
  • TABLE 326. Russia Paediatric Influenza Prevention Market Size, by End User, 2017-